Trastuzumab in metastatic breast cancer

F. Tomao, E. Miele, G. P. Spinelli, M. Russillo, G. La Ferla, S. Tomao

Research output: Contribution to journalArticle


Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.

Original languageEnglish
Pages (from-to)247-249
Number of pages3
JournalEuropean Journal of Gynaecological Oncology
Issue number3
Publication statusPublished - 2006


  • HER2
  • Metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Trastuzumab in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Tomao, F., Miele, E., Spinelli, G. P., Russillo, M., La Ferla, G., & Tomao, S. (2006). Trastuzumab in metastatic breast cancer. European Journal of Gynaecological Oncology, 27(3), 247-249.